Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eisai Inc.
This is a double-blind, placebo-controlled, randomized, parallel group study. Three different doses of APD356 or placebo will be administered daily for 12 weeks, to obese, male and nonpregnant, nonlactating, female volunteers, aged 18 to 65 years. Approximately 400 subjects will be enrolled.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy male or nonpregnant, nonlactating females aged 18-65 years (inclusive)
Body mass index (BMI) of 30-45 kg/m2
Non-smoker
No concomitant medications other than hypertension medications (stable \> 90 days) and/or statins (stable \> 90 days)
No past treatment with drugs associated with the development of pulmonary hypertension or cardiac valvular insufficiency
No more than mild mitral valve regurgitation and absence of aortic valve regurgitation upon screening echocardiogram
Clareo Health | Safety and Efficacy of APD356 in the Treatment of Obesity
